PillRx only · Tablet, Film Coated · Oral
Tranylcypromine Sulfate
Brands: Parnate · Tranylcypromine Sulfate
3 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US3 NDCs
3 active makers
3 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 2 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$0.597
Latest avg · Jul 22, 2026
-13%
Since Dec 17, 2025
3
Active US suppliers
67%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
236
Rx · 2026 Q1
36K
Units dispensed
-23%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it3 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Actavis Pharma, Inc. | unknown | 1 | SUPPLYING |
| Advanz Pharma (US) Corp. | unknown | 1 | SUPPLYING |
| Strides Pharma Science Limited | unknown | 1 | SUPPLYING |
Regulatory & supply eventsFDA · US
Shortages, recalls, and registration changes attached to this drug concept.
- Oct 21, 2025RESOLVEDShortage resolved: Tranylcypromine Sulfate Tablet (Teva Pharmaceuticals USA, Inc.)
Tranylcypromine Sulfate Tablet — reported in shortage by Teva Pharmaceuticals USA, Inc.. Therapeutic category: Psychiatry.
- Oct 21, 2025SHORTAGEDrug shortage: Tranylcypromine Sulfate Tablet (Teva Pharmaceuticals USA, Inc.)
Tranylcypromine Sulfate Tablet — reported in shortage by Teva Pharmaceuticals USA, Inc.. Therapeutic category: Psychiatry.